Abstract
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
Highlights
Standards of care and novel approaches in the management of glioblastoma multiforme Andreas F
We review the standard treatment options for Glioblastoma multiforme (GBM) and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields
This review focuses on the current standards of care and highlights novel therapeutic approaches for the treatment of GBM
Summary
GBMs are highly invasive tumors that are surrounded by peritumoral edema and inflammation. Due to their highly aggressive nature, the tumor margins of GBMs are unclear, and GBMs are usually not amenable to complete resection. As elderly patients with GBM are considered to have a poor prognosis, many clinical trials have been restricted to patients less than 65-70 years of age. The benefit of radiotherapy in elderly patients was confirmed in a randomized trial comparing radiotherapy to best supportive care alone. The median OS increased from 3.9 to 6.9 months with radiotherapy and resulted in a better quality of life[5]. For elderly patients, hypofractionated radiotherapy administered over 15 days
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
